News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
210,865 Results
Type
Article (7543)
Company Profile (39)
Press Release (203283)
Section
Business (56366)
Career Advice (218)
Deals (10765)
Drug Delivery (45)
Drug Development (12702)
Employer Resources (44)
FDA (5846)
Job Trends (5441)
News (88326)
Policy (8746)
Tag
Academia (731)
Alliances (15500)
Alzheimer's disease (297)
Approvals (5862)
Artificial intelligence (95)
Bankruptcy (66)
Best Places to Work (4929)
Biosimilars (34)
Breast cancer (60)
Cancer (339)
Cardiovascular disease (41)
Career advice (201)
Cell therapy (61)
Clinical research (10578)
Collaboration (183)
COVID-19 (724)
C-suite (43)
Data (412)
Diabetes (57)
Diagnostics (3127)
Drug pricing (43)
Earnings (17612)
Employer resources (39)
Events (47530)
Executive appointments (159)
FDA (6119)
Funding (144)
Gene therapy (46)
GLP-1 (140)
Government (1350)
Healthcare (8636)
Infectious disease (758)
Inflammatory bowel disease (34)
IPO (4304)
Job creations (728)
Job search strategy (188)
Layoffs (72)
Legal (1662)
Lung cancer (43)
Manufacturing (57)
Medical device (6156)
Medtech (6156)
Mergers & acquisitions (6579)
Metabolic disorders (159)
Neuroscience (361)
NextGen Class of 2024 (2938)
Non-profit (1571)
Northern California (509)
Obesity (96)
Opinion (63)
People (18542)
Phase I (2242)
Phase II (3703)
Phase III (5071)
Pipeline (155)
Policy (31)
Postmarket research (737)
Preclinical (728)
Radiopharmaceuticals (75)
Rare diseases (75)
Real estate (1430)
Regulatory (6184)
Research institute (646)
Southern California (418)
Startups (1267)
United States (5082)
Vaccines (110)
Weight loss (48)
Date
Today (49)
Last 7 days (234)
Last 30 days (881)
Last 365 days (12224)
2024 (12168)
2023 (13337)
2022 (20481)
2021 (21869)
2020 (21226)
2019 (18117)
2018 (13344)
2017 (9161)
2016 (9761)
2015 (11227)
2014 (8296)
2013 (6813)
2012 (7112)
2011 (7099)
2010 (5710)
Location
Africa (236)
Arizona (54)
Asia (11040)
Australia (1482)
California (1108)
Canada (443)
China (95)
Colorado (75)
Connecticut (78)
Europe (26403)
Florida (198)
Georgia (65)
Illinois (163)
Indiana (103)
Japan (39)
Maryland (146)
Massachusetts (914)
Michigan (66)
Minnesota (93)
Missouri (37)
New Jersey (416)
New York (378)
North Carolina (311)
Northern California (509)
Ohio (44)
Pennsylvania (361)
South America (318)
Southern California (418)
Tennessee (38)
Texas (152)
Utah (62)
Washington State (101)
210,865 Results for "quantum leap healthcare".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer.
October 30, 2023
·
6 min read
Business
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial.
June 28, 2023
·
6 min read
Press Releases
NIKKI’s Efficacy in Overcoming Lyme Disease to be Presented at 2024 Leap into Health Conference
December 13, 2024
·
5 min read
Biotech Bay
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex’s oral paclitaxel plus encequidar in combination with GSK’s dostarlimab in the neoadjuvant setting at this year’s American Society of Clinical Oncology (ASCO) conference.
May 1, 2023
·
4 min read
Press Releases
Quantum Biopharma Announces Closing of First Tranche
December 16, 2024
·
5 min read
Press Releases
IonQ to Highlight Recent Quantum Innovations in Live Webinar, “IonQ’s Full-Stack Quantum Innovation”
November 25, 2024
·
5 min read
Biotech Bay
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.
May 2, 2023
·
7 min read
Press Releases
AI/ML Innovations to Acquire Quantum Sciences Ltd
December 10, 2024
·
4 min read
Press Releases
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment.
September 9, 2024
·
4 min read
Business
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative (“Quantum Leap”) today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.
March 13, 2023
·
5 min read
1 of 21,087
Next
